Rho Kinase: an Important Mediator of Atherosclerosis and Vascular Disease

Overview

Journal Curr Pharm Des

Publisher Bentham Science Publishers

Date 2009 Sep 17

PMID 19754385

Citations 44

Authors

Qian Zhou

James K Liao

Affiliations

Soon will be listed here.

Abstract

Atherosclerosis is a complex inflammatory process characterized by the cross-talk between excessive inflammation and lipid accumulation. In the past few years, compelling evidence suggests that statins can decrease vascular inflammation and attenuate the development of atherosclerosis through their so-called "pleiotropic effects". These cholesterol-independent effects are predominantly due to their ability to inhibit isoprenoid synthesis. In particular, inhibition of geranylgeranylpyrophosphate synthesis leads to inhibition of Rho and its downstream target, Rho-kinase (ROCK). Thus, one of the beneficial effects of statin therapy could be due to inhibitory effects on ROCK. ROCK is involved in mediating diverse cellular functions such as smooth muscle contraction, cell migration and proliferation. While increased ROCK activity is associated with endothelial dysfunction, cerebral ischemia, coronary vasospasms and metabolic syndrome, the inhibition of ROCK by statins or selective ROCK inhibitors leads to up-regulation of endothelial nitric oxide synthase (eNOS), decreased vascular inflammation, and reduced atherosclerotic plaque formation. This review will focus on the impact of ROCK in cardiovascular disease and its contributory role to vascular inflammation and the atherosclerosis.

Citing Articles

How Protein Depletion Balances Thrombosis and Bleeding Risk in the Context of Platelet's Activatory and Negative Signaling.

Montecino-Garrido H, Trostchansky A, Espinosa-Parrilla Y, Palomo I, Fuentes E Int J Mol Sci. 2024; 25(18).

PMID: 39337488 PMC: 11432290. DOI: 10.3390/ijms251810000.

Direct active Fyn-paxillin interaction regulates vascular smooth muscle cell migration.

Zhang Y, Kishi H, Kobayashi S J Smooth Muscle Res. 2023; 59:58-66.

PMID: 37438114 PMC: 10336424. DOI: 10.1540/jsmr.59.58.

Executable models of immune signaling pathways in HIV-associated atherosclerosis.

Palshikar M, Palli R, Tyrell A, Maggirwar S, Schifitto G, Singh M NPJ Syst Biol Appl. 2022; 8(1):35.

PMID: 36131068 PMC: 9492768. DOI: 10.1038/s41540-022-00246-5.

Methyl Ferulic Acid Attenuates Human Cardiac Fibroblasts Differentiation and Myocardial Fibrosis by Suppressing pRB-E2F1/CCNE2 and RhoA/ROCK2 Pathway.

Liao R, Qi Z, Tang R, Wang R, Wang Y Front Pharmacol. 2021; 12:714390.

PMID: 34483923 PMC: 8416034. DOI: 10.3389/fphar.2021.714390.

Myosin Phosphatase Is Implicated in the Control of THP-1 Monocyte to Macrophage Differentiation.

Toth E, Erdodi F, Kiss A Int J Mol Sci. 2021; 22(5).

PMID: 33802280 PMC: 7959147. DOI: 10.3390/ijms22052516.

References

Mohri M, Shimokawa H, Hirakawa Y, Masumoto A, Takeshita A . Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J Am Coll Cardiol. 2003; 41(1):15-9. DOI: 10.1016/s0735-1097(02)02632-3. View

Yoneda A, Multhaupt H, Couchman J . The Rho kinases I and II regulate different aspects of myosin II activity. J Cell Biol. 2005; 170(3):443-53. PMC: 2171463. DOI: 10.1083/jcb.200412043. View

Istvan E, Deisenhofer J . Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001; 292(5519):1160-4. DOI: 10.1126/science.1059344. View

De Simone G, Roman M, Koren M, Mensah G, Ganau A, Devereux R . Stroke volume/pulse pressure ratio and cardiovascular risk in arterial hypertension. Hypertension. 1999; 33(3):800-5. DOI: 10.1161/01.hyp.33.3.800. View

Takeda K, Ichiki T, Tokunou T, Iino N, Fujii S, Kitabatake A . Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb Vasc Biol. 2001; 21(5):868-73. DOI: 10.1161/01.atv.21.5.868. View

Fukumoto Y, Libby P, Rabkin E, Hill C, Enomoto M, Hirouchi Y . Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation. 2001; 103(7):993-9. DOI: 10.1161/01.cir.103.7.993. View

Van Aelst L, DSouza-Schorey C . Rho GTPases and signaling networks. Genes Dev. 1997; 11(18):2295-322. DOI: 10.1101/gad.11.18.2295. View

Wolfrum S, Dendorfer A, Rikitake Y, Stalker T, Gong Y, Scalia R . Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol. 2004; 24(10):1842-7. PMC: 2649731. DOI: 10.1161/01.ATV.0000142813.33538.82. View

Shimokawa H, Morishige K, Miyata K, Kandabashi T, Eto Y, Ikegaki I . Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo. Cardiovasc Res. 2001; 51(1):169-77. DOI: 10.1016/s0008-6363(01)00291-7. View

10.

Riento K, Ridley A . Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 2003; 4(6):446-56. DOI: 10.1038/nrm1128. View

11.

Cho T, Jung Y, Koschinsky M . Apolipoprotein(a), through its strong lysine-binding site in KIV(10'), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway. J Biol Chem. 2008; 283(45):30503-12. PMC: 2662143. DOI: 10.1074/jbc.M802648200. View

12.

Shimizu Y, Thumkeo D, Keel J, Ishizaki T, Oshima H, Oshima M . ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J Cell Biol. 2005; 168(6):941-53. PMC: 2171774. DOI: 10.1083/jcb.200411179. View

13.

Aird W . Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res. 2007; 100(2):158-73. DOI: 10.1161/01.RES.0000255691.76142.4a. View

14.

Laufs U, La Fata V, Plutzky J, Liao J . Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998; 97(12):1129-35. DOI: 10.1161/01.cir.97.12.1129. View

15.

Langer H, Gawaz M . Platelet-vessel wall interactions in atherosclerotic disease. Thromb Haemost. 2008; 99(3):480-6. DOI: 10.1160/TH07-11-0685. View

16.

Sebbagh M, Renvoize C, Hamelin J, Riche N, Bertoglio J, Breard J . Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat Cell Biol. 2001; 3(4):346-52. DOI: 10.1038/35070019. View

17.

Gagne C, Gaudet D, Bruckert E . Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002; 105(21):2469-75. DOI: 10.1161/01.cir.0000018744.58460.62. View

18.

Liu P, Liu Y, Lin L, Chen J, Liao J . Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation. 2008; 119(1):131-8. PMC: 2745913. DOI: 10.1161/CIRCULATIONAHA.108.813311. View

19.

Laurent S, Katsahian S, Fassot C, Tropeano A, Gautier I, Laloux B . Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke. 2003; 34(5):1203-6. DOI: 10.1161/01.STR.0000065428.03209.64. View

20.

Coleman M, Sahai E, Yeo M, Bosch M, Dewar A, Olson M . Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol. 2001; 3(4):339-45. DOI: 10.1038/35070009. View